<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39458251</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-2607</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Microorganisms</Title><ISOAbbreviation>Microorganisms</ISOAbbreviation></Journal><ArticleTitle>Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis-The Elephant Is (Still) in the Room.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1941</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/microorganisms12101941</ELocationID><Abstract><AbstractText>Severe SARS-CoV-2 infections may still be observed in people bearing risk factors, such as the use of anti-CD20 monoclonal antibodies (mAbs), which are adopted in several autoimmune disorders including multiple sclerosis (MS). COVID-19 diagnosis is routinely based on nasopharyngeal swab testing, but suboptimal sensitivity for SARS-CoV-2 detection compared to bronchoalveolar lavage (BAL) may lead to misdiagnosis in some cases. Such diagnostic issues were described in a few MS patients receiving anti-CD20 mAbs, including middle-aged people and lacking information on subsequent MS therapeutic management, a debated topic as no evidence-based guidance on de-risking strategies is currently available. Here, we report the case of a young MS patient who developed severe COVID-19 pneumonia under treatment with the anti-CD20 mAb ocrelizumab, and who was finally diagnosed with SARS-CoV-2 by BAL despite repeatedly negative nasopharyngeal swabs. Ocrelizumab was then discontinued, and treatment with a sphingosine-1 phosphate receptor modulator was started, followed by maintenance of clinical and radiological MS stability. Challenges in diagnosing COVID-19 pneumonia in people without risk factors other than immunomodulatory treatment are hence discussed, as well as potential strategies for de-risking MS therapies. The latter topic is increasingly debated based on raising concerns for potential long-term safety issues of high-efficacy treatments, including anti-CD20 mAbs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mariottini</LastName><ForeName>Alice</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1869-7067</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, 50139 Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology II Unit, Careggi University Hospital, 50134 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lotti</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, 50139 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damato</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, 50139 Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology II Unit, Careggi University Hospital, 50134 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massacesi</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, 50139 Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology II Unit, Careggi University Hospital, 50134 Florence, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Microorganisms</MedlineTA><NlmUniqueID>101625893</NlmUniqueID><ISSNLinking>2076-2607</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B cell depletion</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">anti-CD20</Keyword><Keyword MajorTopicYN="N">bronchoalveolar lavage</Keyword><Keyword MajorTopicYN="N">monoclonal antibody</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">nasopharyngeal swab</Keyword><Keyword MajorTopicYN="N">ocrelizumab</Keyword><Keyword MajorTopicYN="N">pneumonia</Keyword></KeywordList><CoiStatement>A.M. has no conflicts to disclose relevant to the paper; she reports speaker’s honoraria and non-financial support from Sanofi Genzyme, Biogen, Novartis, and Janssen, outside the submitted work. A.L and V.D. have no conflicts of interest relevant to this topic. L.M. has no conflicts to disclose relevant to the paper; he reports personal fees and non-financial support from Biogen, Novartis, Merck Serono, Teva, Sanofi, and Janssen, outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39458251</ArticleId><ArticleId IdType="pmc">PMC11509757</ArticleId><ArticleId IdType="doi">10.3390/microorganisms12101941</ArticleId><ArticleId IdType="pii">microorganisms12101941</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Filip R., Gheorghita Puscaselu R., Anchidin-Norocel L., Dimian M., Savage W.K. Global challenges to public health care systems during the COVID-19 pandemic: A review of pandemic measures and problems. J. Pers. Med. 2022;12:1295. doi: 10.3390/jpm12081295.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12081295</ArticleId><ArticleId IdType="pmc">PMC9409667</ArticleId><ArticleId IdType="pubmed">36013244</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization   [(accessed on 28 August 2024)]; Available online:  https://www.who.int/emergencies/diseases/novel-coronavirus-2019/strategies-and-plans.</Citation></Reference><Reference><Citation>Booth A., Reed A.B., Ponzo S., Yassaee A., Aral M., Plans D., Labrique A., Mohan D. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS ONE. 2021;16:e0247461. doi: 10.1371/journal.pone.0247461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0247461</ArticleId><ArticleId IdType="pmc">PMC7932512</ArticleId><ArticleId IdType="pubmed">33661992</ArticleId></ArticleIdList></Reference><Reference><Citation>Canuti M., Monti M.C., Bobbio C., Muscatello A., Muheberimana T., Baldi S.L., Blasi F., Canetta C., Costantino G., Nobili A. The role of immune suppression in COVID-19 hospitalization: Clinical and epidemiological trends over three years of SARS-CoV-2 epidemic. Front. Med. 2023;10:1260950. doi: 10.3389/fmed.2023.1260950.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1260950</ArticleId><ArticleId IdType="pmc">PMC10513414</ArticleId><ArticleId IdType="pubmed">37746083</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson-Yap S., Pirmani A., Kalincik T., De Brouwer E., Geys L., Parciak T., Helme A., Rijke N., Hillert J.A., Moreau Y. Updated results of the COVID-19 in MS global data sharing initiative: Anti-CD20 and other risk factors associated with COVID-19 severity. Neurol. Neuroimmunol. Neuroinflamm. 2022;9:e200021. doi: 10.1212/NXI.0000000000200021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000200021</ArticleId><ArticleId IdType="pmc">PMC9423711</ArticleId><ArticleId IdType="pubmed">36038263</ArticleId></ArticleIdList></Reference><Reference><Citation>Taton O., Papleux E., Bondue B., Knoop C., Van Laethem S., Bauler A., Martiny D., Montesinos I., Delforge M.-L., Elmaouhab K., et al. Role of the bronchoalveolar lavage in noncritically ill patients during the SARS-CoV-2 epidemic. Pulm. Med. 2020;2020:9012187. doi: 10.1155/2020/9012187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/9012187</ArticleId><ArticleId IdType="pmc">PMC7747005</ArticleId><ArticleId IdType="pubmed">33381313</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrucco F., Carriero A., Falaschi Z., Paschè A., Gavelli F., Airoldi C., Bellan M., Sainaghi P.P., Solidoro P., Balbo P.E. COVID-19 diagnosis in case of two negative nasopharyngeal swabs: Association between chest CT and bronchoalveolar lavage results. Radiology. 2021;298:E152–E155. doi: 10.1148/radiol.2020203776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2020203776</ArticleId><ArticleId IdType="pmc">PMC7903987</ArticleId><ArticleId IdType="pubmed">33399508</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Silva L., Klopfenstein T., Gendrin V., Clouet J., Toko L., Richier Q., Leriche T., Nicolas R., Queijo A., Sreiri N. Prolonged SARS-CoV-2 Infection in patients receiving anti-CD20 monoclonal antibodies: A diagnostic challenged by negative nasopharyngeal RT-PCR and successful treatment with COVID-19 high-titer convalescent plasma. Viruses. 2023;15:2220. doi: 10.3390/v15112220.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15112220</ArticleId><ArticleId IdType="pmc">PMC10675708</ArticleId><ArticleId IdType="pubmed">38005897</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukha Y., Makhoul K., Abu-Elhija J., Hayek T., Hamoud S. A case of severe COVID-19 pneumonia diagnosed in bronchoscopy with negative repeated nasopharyngeal swabs. J. Med. Cases. 2021;12:217. doi: 10.14740/jmc3679.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jmc3679</ArticleId><ArticleId IdType="pmc">PMC8279280</ArticleId><ArticleId IdType="pubmed">34429794</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson E.G., Pender M., Angerbauer M., Cook C., Jones B., Spivak A.M., Spivak E.S., Swaminathan S. Prolonged SARS-CoV-2 illness in a patient receiving ocrelizumab for multiple sclerosis. Open Forum Infect. Dis. 2021;8:ofab176. doi: 10.1093/ofid/ofab176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab176</ArticleId><ArticleId IdType="pmc">PMC8083367</ArticleId><ArticleId IdType="pubmed">34258310</ArticleId></ArticleIdList></Reference><Reference><Citation>Common Terminology Criteria for Adverse Events (CTCAE)  [(accessed on 1 September 2024)]; Available online:  https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.</Citation></Reference><Reference><Citation>Mariottini A., Bertozzi A., Marchi L., Di Cristinzi M., Mechi C., Barilaro A., Massacesi L., Repice A.M. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis. J. Neurol. 2022;269:2840–2847. doi: 10.1007/s00415-022-11003-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11003-3</ArticleId><ArticleId IdType="pmc">PMC8891428</ArticleId><ArticleId IdType="pubmed">35239006</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz J.D., Bouley A.J., Jungquist R.M., Douglas E.A., O’Shea I.L., Lathi E.S. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab. Mult. Scler. Relat. Disord. 2022;57:103382. doi: 10.1016/j.msard.2021.103382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2021.103382</ArticleId><ArticleId IdType="pmc">PMC8575541</ArticleId><ArticleId IdType="pubmed">35158475</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte W.L. Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study. Mult. Scler. Relat. Disord. 2021;52:103014. doi: 10.1016/j.msard.2021.103014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2021.103014</ArticleId><ArticleId IdType="pmc">PMC8102087</ArticleId><ArticleId IdType="pubmed">34000684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes R., Whitley L., Fitovski K., Schneble H.-M., Muros E., Sauter A., Craveiro L., Dillon P., Bonati U., Jessop N., et al. COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult. Scler. Relat. Disord. 2021;49:102725. doi: 10.1016/j.msard.2020.102725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2020.102725</ArticleId><ArticleId IdType="pmc">PMC7772086</ArticleId><ArticleId IdType="pubmed">33482590</ArticleId></ArticleIdList></Reference><Reference><Citation>Januel E., Hajage D., Labauge P., Maillart E., De Sèze J., Zephir H., Pelletier J., Guilloton L., Bensa C., Heinzlef O., et al. Association between anti-CD20 therapies and COVID-19 severity among patients with relapsing-remitting and progressive multiple sclerosis. JAMA Netw. Open. 2023;6:e2319766. doi: 10.1001/jamanetworkopen.2023.19766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.19766</ArticleId><ArticleId IdType="pmc">PMC10290250</ArticleId><ArticleId IdType="pubmed">37351881</ArticleId></ArticleIdList></Reference><Reference><Citation>Weberpals J., Roumpanis S., Barer Y., Ehrlich S., Jessop N., Pedotti R., Vaknin-Dembinsky A., Brill L., Chodick G., Rouzic E.M. Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel. Mult. Scler. Relat. Disord. 2022;68:104153. doi: 10.1016/j.msard.2022.104153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2022.104153</ArticleId><ArticleId IdType="pmc">PMC9422340</ArticleId><ArticleId IdType="pubmed">36081277</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao C.A., Cuttica M.J., Malsin E.S., Argento A.C., Wunderink R.G., Smith S.B., Investigators N.C. Comparing nasopharyngeal and BAL SARS-CoV-2 assays in respiratory failure. Am. J. Respir. Crit. Care Med. 2021;203:127–129. doi: 10.1164/rccm.202008-3137LE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202008-3137LE</ArticleId><ArticleId IdType="pmc">PMC7781122</ArticleId><ArticleId IdType="pubmed">33125256</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha B.K., Saha S., Chong W.H., Beegle S. Indications, clinical utility, and safety of bronchoscopy in COVID-19. Respir. Care. 2022;67:241–251. doi: 10.4187/respcare.09405.</Citation><ArticleIdList><ArticleId IdType="doi">10.4187/respcare.09405</ArticleId><ArticleId IdType="pubmed">34848547</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden M.K., Englund J.A., Lee F., Lee M.J., Loeb M., Morgan D.J., Patel R., El Alayli A., El Mikati I.K., Sultan S., et al.  Infectious Diseases Society of America Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing. Infectious Diseases Society of America 2022; Version 2.0.0.  [(accessed on 21 September 2024)].  Available online:  https://www.idsociety.org/practice-guideline/covid-19-guideline-antigen-testing/</Citation></Reference><Reference><Citation>Hayden M.K., El Mikati I.K., Hanson K.E., Englund J.A., Humphries R.M., Lee F., Loeb M., Morgan D.J., Patel R., Al Ta’ani O., et al. Infectious diseases society of America guidelines on the diagnosis of COVID-19: Serologic testing. Clin. Infect. Dis. 2024;78:e150–e169. doi: 10.1093/cid/ciae121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciae121</ArticleId><ArticleId IdType="pubmed">38489670</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang V., Seery N., Wesselingh R., Yeh W., Zhong M., Tan T., Dwyer C., Nesbitt C., Rath L., Perera D., et al. Neutropaenia complications from ocrelizumab and rituximab treatment. Mult. Scler. Relat. Disord. 2024;81:105147. doi: 10.1016/j.msard.2023.105147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2023.105147</ArticleId><ArticleId IdType="pubmed">38043368</ArticleId></ArticleIdList></Reference><Reference><Citation>Habek M., Piskač D., Gabelić T., Barun B., Adamec I., Krbot Skorić M. Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab. Mult. Scler. Relat. Disord. 2022;62:103798. doi: 10.1016/j.msard.2022.103798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2022.103798</ArticleId><ArticleId IdType="pmc">PMC8994678</ArticleId><ArticleId IdType="pubmed">35429819</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero-Romero S., Lebrun-Frénay C., Reyes S., Amato M.P., Campins M., Farez M., Filippi M., Hacohen Y., Hemmer B., Juuti R., et al. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. Mult. Scler. 2023;29:904–925. doi: 10.1177/13524585231168043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13524585231168043</ArticleId><ArticleId IdType="pmc">PMC10338708</ArticleId><ArticleId IdType="pubmed">37293841</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdaca G., Noberasco G., Olobardi D., Lunardi C., Maule M., Delfino L., Triggiani M., Cardamone C., Benfaremo D., Moroncini G., et al. Current take on systemic sclerosis patients’ vaccination recommendations. Vaccines. 2021;9:1426. doi: 10.3390/vaccines9121426.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9121426</ArticleId><ArticleId IdType="pmc">PMC8708328</ArticleId><ArticleId IdType="pubmed">34960174</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdaca G., Orsi A., Spano F., Faccio V., Puppo F., Durando P., Icardi G., Ansaldi F. Vaccine-preventable infections in systemic lupus erythematosus. Hum. Vaccines Immunother. 2016;12:632–643. doi: 10.1080/21645515.2015.1107685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1107685</ArticleId><ArticleId IdType="pmc">PMC4964666</ArticleId><ArticleId IdType="pubmed">26750996</ArticleId></ArticleIdList></Reference><Reference><Citation>Prosperini L., Haggiag S., Ruggieri S., Tortorella C., Gasperini C. Stopping disease-modifying treatments in multiple sclerosis: A systematic review and meta-analysis of real-world studies. CNS Drugs. 2023;37:915–927. doi: 10.1007/s40263-023-01038-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-023-01038-z</ArticleId><ArticleId IdType="pubmed">37740822</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasca M., Forci B., Mariottini A., Mechi C., Barilaro A., Massacesi L., Repice A.M. Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. Mult. Scler. Relat. Disord. 2021;47:102591. doi: 10.1016/j.msard.2020.102591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2020.102591</ArticleId><ArticleId IdType="pubmed">33142245</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannoni G., Hawkes C.H., Lechner-Scott J., Levy M., Yeh E.A. Beyond the B-cell as a treatment target in multiple sclerosis. Mult. Scler. Relat. Disord. 2023;75:104786. doi: 10.1016/j.msard.2023.104786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2023.104786</ArticleId><ArticleId IdType="pubmed">37295263</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan R., Kilaru A., Hemmer B., Campbell Cree B.A., Greenberg B.M., Kundu U., Hach T., DeLasHeras V., Ward B.J., Berger J. COVID-19 infection in fingolimod-or siponimod-treated patients: Case series. Neurol. Neuroimmunol. Neuroinflamm. 2021;9:e1092. doi: 10.1212/NXI.0000000000001092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001092</ArticleId><ArticleId IdType="pmc">PMC8860466</ArticleId><ArticleId IdType="pubmed">34848501</ArticleId></ArticleIdList></Reference><Reference><Citation>Teymouri S., Pourbayram Kaleybar S., Hejazian S.S., Hejazian S.M., Ansarin K., Ardalan M., Zununi Vahed S. The effect of Fingolimod on patients with moderate to severe COVID-19. Pharmacol. Res. Perspect. 2023;11:e01039. doi: 10.1002/prp2.1039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.1039</ArticleId><ArticleId IdType="pmc">PMC9791159</ArticleId><ArticleId IdType="pubmed">36567519</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy H.M., Batiha G.E.-S., Al-Gareeb A.I., Al-Harcan N.A.H., Welson N.N. Receptor-dependent effects of sphingosine-1-phosphate (S1P) in COVID-19: The black side of the moon. Mol. Cell. Biochem. 2023;478:2271–2279. doi: 10.1007/s11010-023-04658-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-023-04658-7</ArticleId><ArticleId IdType="pmc">PMC9848039</ArticleId><ArticleId IdType="pubmed">36652045</ArticleId></ArticleIdList></Reference><Reference><Citation>Hach T., Shakeri-Nejad K., Bigaud M., Dahlke F., de Micco M., Petricoul O., Graham G., Piani-Meier D., Turrini R., Brinkmann V. Rationale for use of sphingosine-1-phosphate receptor modulators in COVID-19 patients: Overview of scientific evidence. J. Interferon Cytokine Res. 2023;43:246–256. doi: 10.1089/jir.2022.0078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2022.0078</ArticleId><ArticleId IdType="pmc">PMC10282791</ArticleId><ArticleId IdType="pubmed">36454249</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker D., Forte E., Pryce G., Kang A.S., James L.K., Giovannoni G., Schmierer K. The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination. Mult. Scler. Relat. Disord. 2023;69:104425. doi: 10.1016/j.msard.2022.104425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2022.104425</ArticleId><ArticleId IdType="pmc">PMC9678390</ArticleId><ArticleId IdType="pubmed">36470168</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong J., Hertoghs N., Lemle A., Linscheid P., Raghavan N., Singh A., Sidorenko T. COVID-19 antibody response by vaccine type and lymphocyte count in RMS patients on ponesimod: Results from phase 2 long-term extension study AC-058B202 (P12-3.003) Neurology. 2023;100:2380. doi: 10.1212/WNL.0000000000202511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000202511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger T.M., Valenzuela B., Thompson C.D., Ouwerkerk-Mahadevan S., Ruixo J.J.P. Clinical pharmacokinetics of ponesimod, a selective S1P1 receptor modulator, in the treatment of multiple sclerosis. Clin. Pharmacokinet. 2023;62:1533–1550. doi: 10.1007/s40262-023-01308-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-023-01308-5</ArticleId><ArticleId IdType="pubmed">37776485</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran J.Q., Zhang P., Ghosh A., Liu L., Syto M., Wang X., Palmisano M. Single-Dose Pharmacokinetics of ozanimod and its major active metabolites alone and in combination with gemfibrozil, itraconazole, or rifampin in healthy subjects: A randomized, parallel-group, open-label study. Adv. Ther. 2020;37:4381–4395. doi: 10.1007/s12325-020-01473-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-020-01473-0</ArticleId><ArticleId IdType="pubmed">32857315</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruggieri S., Quartuccio M.E., Prosperini L. Ponesimod in the treatment of relapsing forms of multiple sclerosis: An update on the emerging clinical data. Degener. Neurol. Neuromuscul. Dis. 2022;12:61–73. doi: 10.2147/DNND.S313825.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DNND.S313825</ArticleId><ArticleId IdType="pmc">PMC8958267</ArticleId><ArticleId IdType="pubmed">35356493</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabriela-Loredana D., Fred L., Maria A.-T., Alexander K., Kavita G., Ibrahim T., Tatiana S., Janice W., Ludwig K. Disease activity after short-term interruption of ponesimod versus teriflunomide in relapsing multiple sclerosis patients. J. Neurol. Neurosurg. Psychiatry. 2023;94:A68. doi: 10.1136/jnnp-2023-abn.210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2023-abn.210</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertozzi A., Mariottini A., Marchi L., Di Cristinzi M., Nistri R., Damato V., Mechi C., Barilaro A., Massacesi L., Repice A.M. Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience. Mult. Scler. Relat. Disord. 2023;72:104582. doi: 10.1016/j.msard.2023.104582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2023.104582</ArticleId><ArticleId IdType="pmc">PMC9957336</ArticleId><ArticleId IdType="pubmed">36889098</ArticleId></ArticleIdList></Reference><Reference><Citation>da Penha Gomes Gouvea M., Lira Machado K.L.L., de Oliveira Y.G.P., Moulaz I.R., Henriques A.G., Gouveia T.M., Thompson B.P., Lança K.E.M., de Souza Ramos S., Lacerda G.C.C., et al. Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose. Vaccine. 2023;41:6514–6528. doi: 10.1016/j.vaccine.2023.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.08.022</ArticleId><ArticleId IdType="pubmed">37661534</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto S., Oshiro Y., Inamura N., Nemoto T., Horii K., Okudera K., Konishi M., Ozeki M., Mizoue T., Sugiyama H., et al. Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine. Clin. Microbiol. Infect. 2023;29:1201.e1–1201.e5. doi: 10.1016/j.cmi.2023.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.05.020</ArticleId><ArticleId IdType="pmc">PMC10207835</ArticleId><ArticleId IdType="pubmed">37236545</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>